Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

T vs. C	Standard of Care (SoC)	placebo plus SoC	atezolizumab plus nab-paclitaxel	atezolizumab plus paclitaxel	pembrolizumab plus SoC	capivasertib plus paclitaxel	ipatasertib plus paclitaxel	veliparib plus paclitaxel plus carboplatin
Standard of Care (SoC)	---	NA	1.16 0.98; 1.38	0.89 0.70; 1.14	1.12 0.96; 1.32	1.64 1.00; 2.68	1.25 0.78; 2.00	1.22 0.72; 2.07
placebo plus SoC	NA	---	NA	NA	NA	NA	NA	NA
atezolizumab plus nab-paclitaxel	0.86 0.72; 1.02	NA	---	0.77 0.57; 1.04	0.97 0.76; 1.23	1.41 0.84; 2.38	1.08 0.65; 1.77	1.05 0.60; 1.83
atezolizumab plus paclitaxel	1.12 0.88; 1.43	NA	1.30 0.97; 1.76	---	1.26 0.94; 1.68	1.84 1.06; 3.18	1.40 0.82; 2.38	1.37 0.76; 2.44
pembrolizumab plus SoC	0.89 0.76; 1.05	NA	1.03 0.82; 1.31	0.79 0.59; 1.06	---	1.46 0.87; 2.45	1.11 0.68; 1.83	1.09 0.62; 1.89
capivasertib plus paclitaxel	0.61 0.37; 1.00	NA	0.71 0.42; 1.20	0.54 0.31; 0.94	0.69 0.41; 1.15	---	0.76 0.39; 1.51	0.74 0.36; 1.53
ipatasertib plus paclitaxel	0.80 0.50; 1.28	NA	0.93 0.56; 1.54	0.71 0.42; 1.21	0.90 0.55; 1.48	1.31 0.66; 2.59	---	0.98 0.48; 1.98
veliparib plus paclitaxel plus carboplatin	0.82 0.48; 1.39	NA	0.95 0.55; 1.66	0.73 0.41; 1.31	0.92 0.53; 1.60	1.34 0.65; 2.77	1.02 0.51; 2.08	---

pathologies: 60 - treatments: 1252 result logic